DIVISLAB logo

Divi's Laboratories Limited Stock Price

NSEI:DIVISLAB Community·₹1.6t Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

DIVISLAB Share Price Performance

₹6,104.50
700.15 (12.96%)
21.2% undervalued intrinsic discount
₹7,750.00
Fair Value
₹6,104.50
700.15 (12.96%)
22.0% undervalued intrinsic discount
₹7,825.00
Fair Value
Price ₹6,104.50
AnalystHighTarget ₹7,825.00
AnalystConsensusTarget ₹6,362.79
AnalystLowTarget ₹4,304.58

DIVISLAB Community Narratives

AnalystHighTarget·
Fair Value ₹7.75k 21.2% undervalued intrinsic discount

Custom Synthesis And Green Chemistry Will Harness Rising Pharmaceutical Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹6.36k 4.1% undervalued intrinsic discount

Custom Synthesis And Capacity Expansion Will Unlock Global Demand

1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AnalystLowTarget·
Fair Value ₹4.76k 28.4% overvalued intrinsic discount

Rising Protectionism And Regulatory Burdens Will Undermine Pharma Exports

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent DIVISLAB News & Updates

Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk

Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk

Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation

Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation

Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results

Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results

Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected

Apr 10
Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected

Divi's Laboratories Limited Key Details

₹96.5b

Revenue

₹38.3b

Cost of Revenue

₹58.2b

Gross Profit

₹35.2b

Other Expenses

₹23.1b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
86.87
Gross Margin
60.34%
Net Profit Margin
23.89%
Debt/Equity Ratio
0.03%

Divi's Laboratories Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with proven track record and pays a dividend.

1 Risk
2 Rewards

About DIVISLAB

Founded
1990
Employees
10542
CEO
Kiran Divi
WebsiteView website
www.divislabs.com

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.8%
  • 3 Months: -1.3%
  • 1 Year: -2.3%
  • Year to Date: 1.1%
The market has climbed 1.8% in the last 7 days, lead by the Financials sector with a gain of 2.6%. The market has been flat overall in the last year. Earnings are forecast to grow by 16% annually. Market details ›